Skip to main content

The Immune System

Under Control

Our Company

AbolerIS Pharma is a Belgian biopharmaceutical company developing a novel approach to the treatment of chronic autoimmune and inflammatory diseases.

Lead Program

AbolerIS Pharma is developing a first-in-class monoclonal antibody based on a novel scientific approach to restore the balance in the immune system.
Our novel and unique therapeutic approaches induce immune tolerance and preserve useful immune responses in inflammatory, autoimmune, and degenerative diseases.

Latest updates

AbolerIS Pharma is one of the laureates of the REACT-EU program 2022

| sticky | No Comments
Nantes, France, November 22, 2022 – AbolerIS Pharma is a pre-clinical stage biotech company specialized in the development of innovative immunomodulators for the treatment of transplant rejection, graft-versus-host-disease and auto-immune…

EULAR Congress 2024

| Event | No Comments
12 - 15, June 2024 Vienna, Austria About EULAR The European Alliance of Associations for Rheumatology, EULAR, is the organisation which represents the patient, health professional and scientific societies of…

AbolerIS is 4 years old!

| News | No Comments
🎉 Happy 4th Birthday AbolerIS Pharma🎈 Over the past four years, we've evolved, overcome challenges, and embraced new opportunities. May the coming years be filled with even more accomplishments, adventures, and…